Tanzania - English - Tanzania Medicinces & Medical Devices Authority

alkem laboratories limited, india - cefixime - tablets - 200 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

alkem laboratories limited, india - cefixime - capsules - 400 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ascend laboratories sdn bhd - amoxicilin trihydrate; potassium clavulanate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ascend laboratories sdn bhd - mycophenolate mofetil -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ascend laboratories sdn bhd - mycophenolate mofetil -

Kenya - English - Pharmacy and Poisons Board

alkem laboratories ltd alkem house, senapati bapat marg, lower parel, - ofloxacin usp and ornidazole ih - film-coated tablet - each film coated tablet contains: ofloxacin usp… - ofloxacin and ornidazole

Philippines - English - FDA (Food And Drug Administration)

alkem laboratories limited - losartan potassium - film-coated tablet - 50mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

alkem laboratories limited, india - amoxicillin , clavulanic acid - powder for suspension for injection - 1.2g

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; isopropyl alcohol; dichloromethane; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - alkem-amoxiclav tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to alkem-amoxiclav tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to alkem-amoxiclav tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; dichloromethane; magnesium stearate; isopropyl alcohol; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - alkem-amoxiclav tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to alkem-amoxiclav tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to alkem-amoxiclav tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.